In the third part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Laura Johnson, senior director of ...

FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.

James D. Chambers, PhD, MPharm, MSc, professor of medicine at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, dives into why biosimilars contribute to a reduction ...

In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Laura Johnson, senior director of sales, life sciences, Loftware, comments on other concepts that are powering ...

Many would agree that over the past five years or so, telehealth has skyrocketed in popularity, as another way to provide clinical healthcare, increasing access to mental health and managed care. 1-4 ...

Leaders with top third-party logistics providers discuss the evolving landscape for the sector in 2025—and the new strides made in their quest to help transform the pharma supply chain. Third-party ...

The timing for the potential tax is yet to be determined, as the industry awaits to see the impact it could bring. The tariffs—if they do take effect—are expected to rise over the next year. The same ...

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jim Shehan, chair of the FDA regulatory practice at Lowenstein Sandler, explains how he anticipates the evolving ...

Click the title above for a link to open the Pharmaceutical Commerce February 2025 issue in an interactive PDF format.

2025 is upon us, officially marking a quarter of a century since Y2K and the midpoint of the decade. There is no doubt that time does quickly fly by, and with that, the February issue of ...